EGFR and non-small cell lung carcinoma: A recent report of AURA-3 in a randomized phase III clinical trial revealed that osimertinib represents the standard therapy in NSCLC with EGFR-activating mutation after the failure of first-line EGFR-TKIs compared to platinum-based chemotherapy [99].